Clinical trials
Trials in Indonesia with no applicable phase and unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
122 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 4 |
| 2018 | 7 |
| 2019 | 8 |
| 2020 | 17 |
| 2021 | 19 |
| 2022 | 19 |
| 2023 | 23 |
| 2024 | 13 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 122 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Indonesia University | 36 |
| Gadjah Mada University | 7 |
| SEAMEO Regional Centre for Food and Nutrition | 7 |
| Dr Cipto Mangunkusumo General Hospital | 6 |
| Dr.dr.Irma Bernadette, SpKK (K) | 6 |
| Hasanuddin University | 6 |
| Fakultas Kedokteran Universitas Indonesia | 5 |
| Dr. Soetomo General Hospital | 3 |
| National Cardiovascular Center Harapan Kita Hospital Indonesia | 2 |
| Trisakti University | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Obesity | 9 |
| Growth Disorders | 5 |
| COVID-19 | 4 |
| Anemia | 3 |
| Diabetes Mellitus, Type 2 | 3 |
| Insulin Resistance | 3 |
| Acne Vulgaris | 2 |
| Acquired Immunodeficiency Syndrome | 2 |
| Alopecia | 2 |
| Anemia, Iron-Deficiency | 2 |
Trials
Showing 1 to 25 of 122. Each trial links to its page on Pharma Observatory.
22 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.